Drug Trial Radar · NCT07170800
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 19, 2025
Primary completion
Feb 28, 2026
Study completion Sep 4, 2026
Sponsor
- Lead sponsor
- WestVac Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
Conditions
- Tuberculosis
- Multidrug Resistant Pulmonary Tuberculosis
- Rifampicin-resistant Tuberculosis
Interventions
JDB0131 100mgDrug
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
JDB0131 200mgDrug
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 200 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
Delamanid (D)Drug
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. Delamanid (D): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients with Sputum Culture Conversion (SCC)Time frame: During the 8-week treatment period and after treatment
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital, Capital Medical University
Beijing, China · Recruiting
Huashan Hospital Fudan University
Shanghai, China · Not yet recruiting
Wuhan Pulmonary Hospital
Wuhan, Hubei, China · Recruiting
Changsha Central Hospital
Changsha, Hunan, China · Recruiting
The Second Hospital of Nanjing
Nanjing, Jiangsu, China · Recruiting
Shandong Public Health Clinical Center
Jinan, Shandong, China · Recruiting
Public Health Clinical Center of Chengdu
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.